Kenya Prepares for Trials of First Locally Made Vaccines by 2027

Nairobi, Kenya – In a significant leap toward self-reliant healthcare, Kenya BioVax Institute is preparing to launch trials for the nation’s first locally manufactured vaccines within the next two years. The initiative is backed by a KSh 8 billion (US$62 million) World Bank package. The move aims to improve access to vital immunizations for children and reduce dependence on international suppliers. 

Targets and Timelines

• Trials for three vaccines—aimed at protecting children against pneumonia and typhoid—are expected to begin by 2027. 

• Kenya currently depends heavily on donors for vaccines; over 80% of the KSh 15 billion spent annually is donor-funded—a figure that is expected to decline as the country advances toward middle-income status and shifts funding priorities. 

Strategic Foundations and Collaborations

• Kenya BioVax recently submitted a feasibility study for a “smart vaccine manufacturing” facility. The study was prepared by the Kenya Vaccine Consortium, which includes notable partners such as AtkinsRéalis, SK Bioscience, and the International Vaccine Institute (IVI). 

• The feasibility report outlines the need for modern manufacturing infrastructure, strengthened regulatory and pharmacovigilance standards, and alignment with global best practices. 

What This Means for Kenya and the Region

• The initiative aligns with Africa’s New Public Health Order, which stresses local production capacity in partnership with the Africa CDC and the African Union.

• Establishing vaccine manufacturing capabilities will bolster Kenya’s health security, lower costs, and position the country strategically within Africa’s vaccine ecosystem.

• The Africa CDC estimates the continent’s vaccine market could grow to USD 2.4–5.6 billion by 2030, but Africa still imports up to 98% of its vaccines—making Kenya’s venture both timely and critical. 

Snapshot Table